C2N Launches Trial for Alzheimer’s Detection Test
C2N Diagnostics is experiencing a couple of breakthroughs with its Alzheimerâs disease detection test - one courtesy of FDA. The agency, which is slowly rising back to full strength after the temporary government shutdown, granted the St. Louis-based company breakthrough device designation for a brain amyloidosis blood test.
Читать дальше...